Dengvaxia, manufactured by French pharmaceutical giant Sanofi, secured its first regulatory approval in Mexico a fortnight ago and is currently being reviewed by around 20 countries in Asia and Latin America.
The Philippines became the first Asian country to approve the sale of the world's first-ever dengue vaccine. It is hoped the drug could eventually help prevent millions of deaths from dengue, the world's fastest-growing mosquito-borne disease. The World Health Organization says as many as 400 million people are infected worldwide every year, and two-thirds are in Asia.
"It's a major step in the prevention of dengue and for public health," Olivier Charmeil, head of Sanofi's vaccines division, said in a statement. Scientists have long been stumped by dengue, which has four separate strains, forcing researchers to find a drug able to fight all of them at once.
It was also found to reduce the risk of hospitalisation by 80 percent. Dengue can trigger a crippling fever, along with muscle and joint pain. There is no known cure, and children are at particular risk. The deadliest form of the disease kills 22,000 people a year, the WHO says.
It was once considered a disease of the tropics, endemic in only nine countries, but globalisation, urbanisation, climate change and jet travel are helping it to move into more temperate zones.
It is now endemic in more than 100 countries. The WHO says cases have risen 30-fold over the last 50 years, with more than half the world's population potentially at risk.
Several million doses of the vaccine are ready to ship, and Sanofi expects annual production to reach 100 million doses by 2017. Sanofi's research and development work took 20 years, costing more than 1.5 billion euros ($1.6 billion).
But the vaccine could bring the company more than $1 billion annually starting in 2018 or 2019, analysts said. Other pharmaceutical companies are developing dengue vaccines, including US firm Merck, Japan's Takeda and Britain's GlaxoSmithKline, but Sanofi is ahead of the competition.